Only tucatinib [eighteen], lapatinib, and neratinib ended up investigated in possible experiments and showed great reaction charges and response length. From the HER2CLIMB trial the secondary endpoint of PFS in clients with brain metastases showed a significant reduction in the chance of development or death by 52% from the tucatinib arm. During